TRIAL DETAIL

MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT

Drug:
Trial Name:
MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Completed
Phase:
1
Start Date 10/01/2016
Age of Trial (yrs) 8.2
Treatment Phase:
Gleevec-resistant
Drug Category:
Theranostic
Strategy:
Radio labeled tracer for GRPR expressing malignancies
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
MITIGATE-NeoBOMB1
Sponsor:
Medical University Innsbruck
Patient Contact:
Clemems Decristoforo, Univ.-Doz.Dr 0043512504 ext 80951 clemens.decristoforo@tirol-kliniken.at Leonhard Gruber, Dr.med. 0043512504 ext 82307 leonhard.gruber@i-med.ac.at
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Subcutaneous
Trial Notes:
This trial is for diagnostics only. It is not therapeutic. Plans were to conclude the MITIGATE project in the Fall of 2017. The ClinicalTrials.gov trial listing has not been updated since the trial was first listed in October, 2016. We will keep the trial status as 'Recruiting' until we get more information.

Trial Links
 
 

Trial Results
 

Drug Information
Advanced Acelerator Applications Pipeline
 
Peptide Receptor Radionuclide Therapy - Prospects for Personalised Treatment
 
MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
 
Imaging Properties and Tumor Targeting of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
 

Trial Sites

Name
Address
City
State
Zip
Country
Innsbruck
6020
Austria